Myriad Genetics, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Raises $10 mil. from the sale of 658,030 shares to collaborative partner Schering Berlin and Swiss investor Friedli Corporate Finance. Schering is collaborating with Myriad under an October 1998 agreement covering Myriad's ProNet technologies for drug target identification. "The funds will allow us to accelerate drug discovery within [the] Myriad Pharmaceuticals, Inc." subsidiary, Myriad says